tubastatin A [Ligand Id: 9702] activity data from GtoPdb and ChEMBL

Click here for a description of the charts and data table

Please tell us if you are using this feature and what you think!

ChEMBL ligand: CHEMBL2018302 (Tubastatin A)
  • histone deacetylase 1/Histone deacetylase 1 in Human [ChEMBL: CHEMBL325] [GtoPdb: 2658] [UniProtKB: Q13547]
  • This target only has 1 pki data point
1 CHEMBL2018302_lig_chart_1 Histone deacetylase 1 Human
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 10/Histone deacetylase 10 in Human [ChEMBL: CHEMBL5103] [GtoPdb: 2614] [UniProtKB: Q969S8]
  • This target only has 0 pki data point
2 CHEMBL2018302_lig_chart_2 Histone deacetylase 10 Human
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 11/Histone deacetylase 11 in Human [ChEMBL: CHEMBL3310] [GtoPdb: 2615] [UniProtKB: Q96DB2]
  • This target only has 0 pki data point
3 CHEMBL2018302_lig_chart_3 Histone deacetylase 11 Human
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 2/Histone deacetylase 2 in Human [ChEMBL: CHEMBL1937] [GtoPdb: 2616] [UniProtKB: Q92769]
  • This target only has 0 pki data point
4 CHEMBL2018302_lig_chart_4 Histone deacetylase 2 Human
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 3/Histone deacetylase 3 in Human [ChEMBL: CHEMBL1829] [GtoPdb: 2617] [UniProtKB: O15379]
  • This target only has 0 pki data point
5 CHEMBL2018302_lig_chart_5 Histone deacetylase 3 Human
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 3/Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2) in Human [ChEMBL: CHEMBL2111363] [GtoPdb: 2617] [UniProtKB: O15379Q9Y618]
  • This target only has 0 pki data point
6 CHEMBL2018302_lig_chart_6 Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2) Human
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 4/Histone deacetylase 4 in Human [ChEMBL: CHEMBL3524] [GtoPdb: 2659] [UniProtKB: P56524]
  • This target only has 0 pki data point
7 CHEMBL2018302_lig_chart_7 Histone deacetylase 4 Human
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 5/Histone deacetylase 5 in Human [ChEMBL: CHEMBL2563] [GtoPdb: 2660] [UniProtKB: Q9UQL6]
  • This target only has 0 pki data point
8 CHEMBL2018302_lig_chart_8 Histone deacetylase 5 Human
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 6/Histone deacetylase 6 in Human [ChEMBL: CHEMBL1865] [GtoPdb: 2618] [UniProtKB: Q9UBN7]
9 CHEMBL2018302_lig_chart_9 Histone deacetylase 6 Human
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 7/Histone deacetylase 7 in Human [ChEMBL: CHEMBL2716] [GtoPdb: 2661] [UniProtKB: Q8WUI4]
  • This target only has 0 pki data point
10 CHEMBL2018302_lig_chart_10 Histone deacetylase 7 Human
There should be some charts here, you may need to enable JavaScript!
  • Histone deacetylase 8 in Schistosoma mansoni [ChEMBL: CHEMBL3797017] [UniProtKB: A5H660]
  • histone deacetylase 8/Histone deacetylase 8 in Human [ChEMBL: CHEMBL3192] [GtoPdb: 2619] [UniProtKB: Q9BY41]
  • This target only has 1 pki data point
11 CHEMBL2018302_lig_chart_11 Histone deacetylase 8 Schistosoma mansoniHuman
There should be some charts here, you may need to enable JavaScript!
  • histone deacetylase 9/Histone deacetylase 9 in Human [ChEMBL: CHEMBL4145] [GtoPdb: 2620] [UniProtKB: Q9UKV0]
  • This target only has 0 pki data point
12 CHEMBL2018302_lig_chart_12 Histone deacetylase 9 Human
There should be some charts here, you may need to enable JavaScript!
DB Assay description Assay Type Standard value Standard parameter Original value Original units Original parameter Reference
histone deacetylase 1/Histone deacetylase 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL325] [GtoPdb: 2658] [UniProtKB: Q13547]
ChEMBL Inhibition of human HDAC1 B 5.42 pKi 3823.3 nM Ki Bioorg. Med. Chem. (2015) 23: 5151-5155 [PMID:25637120]
ChEMBL Inhibition of HDAC1 (unknown origin) B 4.79 pIC50 16400 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL Inhibition of human recombinant HDAC1 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate B 4.79 pIC50 16400 nM IC50 J. Med. Chem. (2012) 55: 9891-9899 [PMID:23009203]
ChEMBL Inhibition of human recombinant full-length HDAC1 (1 to 482 residues) expressed in baculovirus using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 4.79 pIC50 16400 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of human recombinant HDAC1 protein using RHKKAc from p53 as substrate B 4.79 pIC50 16400 nM IC50 J. Med. Chem. (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of human recombinant HDAC1 expressed in baculovirus/sf9 cells using RHKKAc as substrate B 4.79 pIC50 16400 nM IC50 J. Med. Chem. (2013) 56: 6775-6791 [PMID:23905680]
ChEMBL Inhibition of human recombinant HDAC1 using RHKKAc as substrate B 4.79 pIC50 16400 nM IC50 J. Med. Chem. (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL Inhibition of full length GST-tagged human HDAC1 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay B 4.79 pIC50 16400 nM IC50 Bioorg. Med. Chem. Lett. (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Inhibition of HDAC1 (unknown origin) B 4.79 pIC50 16400 nM IC50 Eur. J. Med. Chem. (2015) 96: 340-359 [PMID:25899338]
ChEMBL Inhibition of human recombinant HDAC1 using RHKKAc peptide as substrate incubated for 5 to mins prior to substrate addition measured after 2 hrs B 4.79 pIC50 16400 nM IC50 J. Med. Chem. (2012) 55: 639-651 [PMID:22165909]
ChEMBL Inhibition of recombinant human HDAC1 using Fluor de Lys-SIRT1 as substrate incubated for 15 mins by fluorescence assay B 4.84 pIC50 14350 nM IC50 Eur. J. Med. Chem. (2016) 116: 126-135 [PMID:27060764]
GtoPdb - - 4.86 pIC50 13800 nM IC50 US8748451. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.86 pIC50 13800 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 expressed in Sf21 cells using RHKK(Ac) as substrate after 60 mins by fluorimetric method B 5 pIC50 >10000 nM IC50 Eur J Med Chem (2017) 127: 115-127 [PMID:28038324]
ChEMBL Inhibition of recombinant human KDAC1 using acetylated p53 (379 to 382 residues) as substrate by fluorescence assay B 5.54 pIC50 2870 nM IC50 J. Med. Chem. (2016) 59: 1613-1633 [PMID:26681404]
ChEMBL Inhibition of HDAC1 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA B 5.57 pIC50 2700 nM IC50 ACS Med Chem Lett (2017) 8: 281-286 [PMID:28337317]
ChEMBL Inhibition of HDAC1 in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method B 5.57 pIC50 2700 nM IC50 Eur J Med Chem (2018) 143: 1790-1806 [PMID:29150330]
ChEMBL Inhibition of human recombinant GST-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using MOCPAC as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis B 5.7 pIC50 >2000 nM IC50 Bioorg Med Chem Lett (2016) 26: 4955-4959 [PMID:27650925]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 5.85 pIC50 1400 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
ChEMBL Inhibition of HDAC1 in human SHSY5Y cells using MOCPAC as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis B 5.95 pIC50 1109.7 nM IC50 Bioorg Med Chem Lett (2016) 26: 4955-4959 [PMID:27650925]
ChEMBL Inhibition of HDAC1 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay B 6.84 pIC50 144 nM IC50 J. Med. Chem. (2013) 56: 1772-1776 [PMID:23368884]
histone deacetylase 10/Histone deacetylase 10 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5103] [GtoPdb: 2614] [UniProtKB: Q969S8]
ChEMBL Inhibition of HDAC10 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of human recombinant HDAC10 expressed in baculovirus/sf9 cells using RHKKAc as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 6775-6791 [PMID:23905680]
ChEMBL Inhibition of human recombinant HDAC10 using RHKKAc as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL Inhibition of N-terminal GST-tagged human HDAC10 (1 to 481 residues) using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Bioorg. Med. Chem. Lett. (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.52 pIC50 >30000 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of human recombinant HDAC10 protein using RHKKAc from p53 as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of HDAC10 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 5.43 pIC50 3710 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
histone deacetylase 11/Histone deacetylase 11 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3310] [GtoPdb: 2615] [UniProtKB: Q96DB2]
ChEMBL Inhibition of HDAC11 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of human recombinant HDAC11 expressed in baculovirus/sf9 cells using RHKKAc as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 6775-6791 [PMID:23905680]
ChEMBL Inhibition of human recombinant HDAC11 using RHKKAc as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL Inhibition of full length N-terminal GST-tagged human HDAC11 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Bioorg. Med. Chem. Lett. (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.52 pIC50 >30000 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of human recombinant HDAC11 protein using RHKKAc from p53 as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of HDAC11 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 5.42 pIC50 3790 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
histone deacetylase 2/Histone deacetylase 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1937] [GtoPdb: 2616] [UniProtKB: Q92769]
ChEMBL Inhibition of HDAC2 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL Inhibition of human recombinant full-length C-terminal GST-tagged HDAC2 expressed in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of human recombinant HDAC2 expressed in baculovirus/sf9 cells using RHKKAc as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 6775-6791 [PMID:23905680]
ChEMBL Inhibition of human recombinant HDAC2 using RHKKAc as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL Inhibition of full length C-terminal 6x-His tagged human HDAC2 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Bioorg. Med. Chem. Lett. (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.52 pIC50 >30000 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of human recombinant HDAC2 protein using RHKKAc from p53 as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of full length human recombinant C-terminal GST-tagged HDAC2 expressed in insect cells using RHKK(Ac) as substrate after 60 mins by fluorimetric method B 5 pIC50 >10000 nM IC50 Eur J Med Chem (2017) 127: 115-127 [PMID:28038324]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 5.2 pIC50 6270 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
ChEMBL Inhibition of HDAC2 in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method B 5.41 pIC50 3900 nM IC50 Eur J Med Chem (2018) 143: 1790-1806 [PMID:29150330]
ChEMBL Inhibition of HDAC2 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA B 5.41 pIC50 3900 nM IC50 ACS Med Chem Lett (2017) 8: 281-286 [PMID:28337317]
ChEMBL Inhibition of HDAC2 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay B 6.44 pIC50 360 nM IC50 J. Med. Chem. (2013) 56: 1772-1776 [PMID:23368884]
histone deacetylase 3/Histone deacetylase 3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1829] [GtoPdb: 2617] [UniProtKB: O15379]
ChEMBL Inhibition of HDAC3 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL Inhibition of full length C-terminal 6x-His tagged human HDAC3 using Arg-His-Lys-Lys(Ac) substrate incubated for 2 hrs by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Bioorg. Med. Chem. Lett. (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.52 pIC50 >30000 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of human recombinant full-length C-terminal GST-tagged HDAC3 expressed in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of HDAC3 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA B 5.54 pIC50 2900 nM IC50 ACS Med Chem Lett (2017) 8: 281-286 [PMID:28337317]
ChEMBL Inhibition of HDAC3 in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method B 5.54 pIC50 2900 nM IC50 Eur J Med Chem (2018) 143: 1790-1806 [PMID:29150330]
ChEMBL Inhibition of HDAC3 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay B 6.81 pIC50 155 nM IC50 J. Med. Chem. (2013) 56: 1772-1776 [PMID:23368884]
histone deacetylase 3/Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2) in Human (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL2111363] [GtoPdb: 2617] [UniProtKB: O15379Q9Y618]
ChEMBL Inhibition of HDAC3/NcoR2 (unknown origin) using RHKKAc from p53 as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of HDAC3/NcoR2 (unknown origin) using RHKKAc as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 5.9 pIC50 1270 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
ChEMBL Inhibition of recombinant human KDAC3/NcoR2 using acetylated p53 (379 to 382 residues) as substrate by fluorescence assay B 6.11 pIC50 770 nM IC50 J. Med. Chem. (2016) 59: 1613-1633 [PMID:26681404]
histone deacetylase 4/Histone deacetylase 4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3524] [GtoPdb: 2659] [UniProtKB: P56524]
ChEMBL Inhibition of HDAC4 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of human recombinant HDAC4 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of human recombinant HDAC4 using acetyl-Lys(trifluoroacetyl)-AMC as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL Inhibition of N-terminal GST-tagged human HDAC4 (627 to 1085 residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Bioorg. Med. Chem. Lett. (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.52 pIC50 >30000 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of HDAC4 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.76 pIC50 17300 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
ChEMBL Inhibition of HDAC4 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay B 5.96 pIC50 1100 nM IC50 J. Med. Chem. (2013) 56: 1772-1776 [PMID:23368884]
histone deacetylase 5/Histone deacetylase 5 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2563] [GtoPdb: 2660] [UniProtKB: Q9UQL6]
ChEMBL Inhibition of HDAC5 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of human recombinant HDAC5 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of human recombinant HDAC5 using acetyl-Lys(trifluoroacetyl)-AMC as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL Inhibition of C-terminal 6x-His tagged human HDAC5 (657 to 1123 residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Bioorg. Med. Chem. Lett. (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.52 pIC50 >30000 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of HDAC5 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 5.47 pIC50 3350 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
ChEMBL Inhibition of HDAC5 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay B 5.64 pIC50 2300 nM IC50 J. Med. Chem. (2013) 56: 1772-1776 [PMID:23368884]
histone deacetylase 6/Histone deacetylase 6 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1865] [GtoPdb: 2618] [UniProtKB: Q9UBN7]
ChEMBL Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus-infected Sf9 insect cells using RHKK(Ac)AMC as substrate after 90 mins by fluorimeter B 8.12 pKi 7.56 nM Ki J Med Chem (2018) 61: 3454-3477 [PMID:29589441]
ChEMBL Inhibition of human HDAC6 B 8.48 pKi 3.3 nM Ki Bioorg. Med. Chem. (2015) 23: 5151-5155 [PMID:25637120]
ChEMBL Inhibition of HDAC6 in human HeLa cells assessed as reduction in K40 hyperacetylation of alpha-tubulin incubated for 6 hrs by immunofluorescence assay B 5.6 pIC50 2500 nM IC50 Bioorg. Med. Chem. Lett. (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Inhibition of HDAC6 (unknown origin) after 60 mins by fluorescence assay B 6.52 pIC50 <300 nM IC50 J. Med. Chem. (2013) 56: 4816-4820 [PMID:23672185]
ChEMBL Inhibition of HDAC6 in human SHSY5Y cells using BATCP as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis B 7.03 pIC50 94.3 nM IC50 Bioorg Med Chem Lett (2016) 26: 4955-4959 [PMID:27650925]
ChEMBL Inhibition of human recombinant HDAC6 expressed in baculovirus infected insect cells using BATCP as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis B 7.46 pIC50 34.9 nM IC50 Bioorg Med Chem Lett (2016) 26: 4955-4959 [PMID:27650925]
ChEMBL Inhibition of HDAC6 in human HeLa-S3 cell lysates preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 40 mins by fluorimetric method B 7.51 pIC50 31 nM IC50 Eur J Med Chem (2018) 143: 1790-1806 [PMID:29150330]
ChEMBL Inhibition of HDAC6 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA B 7.51 pIC50 31 nM IC50 ACS Med Chem Lett (2017) 8: 281-286 [PMID:28337317]
ChEMBL Inhibition of human recombinant N-terminal GST-tagged full length HDAC6 expressed in insect SF9 cells using fluorogenic ZMAL as substrate after 90 mins by fluorescence-based assay B 7.52 pIC50 30.4 nM IC50 Eur J Med Chem (2018) 157: 127-138 [PMID:30092367]
ChEMBL Inhibition of recombinant human HDAC6 using Fluor de Lys-SIRT1 as substrate incubated for 15 mins by fluorescence assay B 7.54 pIC50 28.88 nM IC50 Eur. J. Med. Chem. (2016) 116: 126-135 [PMID:27060764]
ChEMBL Inhibition of recombinant human HDAC6 using fluorogenic HDAC substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins by fluorescence analysis B 7.7 pIC50 20 nM IC50 Bioorg Med Chem (2018) 26: 5718-5729 [PMID:30385227]
ChEMBL Inhibition of human recombinant HDAC6 using RHKKAc as substrate B 7.82 pIC50 15 nM IC50 J. Med. Chem. (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL Inhibition of HDAC6 (unknown origin) B 7.82 pIC50 15 nM IC50 Bioorg. Med. Chem. Lett. (2014) 24: 4826-4830 [PMID:25240614]
ChEMBL Inhibition of recombinant human HDAC6 using RHKKAc as substrate by fluorescence assay B 7.82 pIC50 15 nM IC50 J. Med. Chem. (2015) 58: 7611-7633 [PMID:26086931]
ChEMBL Inhibition of recombinant human HDAC-6 using RHKKAc as substrate B 7.82 pIC50 15 nM IC50 MedChemComm (2012) 3: 135-161
ChEMBL Inhibition of recombinant N-GST-tagged HDAC6 (unknown origin) assessed as reduction in deacetylation of Ac-Arg-Gly-Lys(Ac)-AMC substrate by fluorescence assay B 7.82 pIC50 15 nM IC50 Bioorg. Med. Chem. Lett. (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Inhibition of human recombinant HDAC6 expressed in baculovirus/sf9 cells using RHKKAc as substrate B 7.82 pIC50 15 nM IC50 J. Med. Chem. (2013) 56: 6775-6791 [PMID:23905680]
ChEMBL Inhibition of human recombinant HDAC6 protein using RHKKAc from p53 as substrate B 7.82 pIC50 15 nM IC50 J. Med. Chem. (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of HDAC6 (unknown origin) B 7.82 pIC50 15 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL Inhibition of human recombinant full-length HDAC6 expressed in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 7.82 pIC50 15 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of HDAC6 (unknown origin) B 7.82 pIC50 15 nM IC50 Eur J Med Chem (2018) 150: 506-524 [PMID:29549837]
ChEMBL Inhibition of human recombinant HDAC6 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate B 7.82 pIC50 15 nM IC50 J. Med. Chem. (2012) 55: 9891-9899 [PMID:23009203]
ChEMBL Inhibition of human recombinant HDAC6 using RHKKAcAMC as substrate by fluorescence assay B 7.82 pIC50 15 nM IC50 Eur J Med Chem (2018) 152: 329-357 [PMID:29738953]
ChEMBL Inhibition of human recombinant HDAC6 using RHKKAc peptide as substrate incubated for 5 to mins prior to substrate addition measured after 2 hrs B 7.82 pIC50 15 nM IC50 J. Med. Chem. (2012) 55: 639-651 [PMID:22165909]
GtoPdb - - 7.85 pIC50 14 nM IC50 US8748451. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 7.85 pIC50 14 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of recombinant human KDAC6 using acetylated p53 (379 to 382 residues) as substrate by fluorescence assay B 7.85 pIC50 14 nM IC50 J. Med. Chem. (2016) 59: 1613-1633 [PMID:26681404]
ChEMBL Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 expressed in Sf9 cells using RHKK(Ac) as substrate after 90 mins by fluorimetric method B 7.86 pIC50 13.7 nM IC50 Eur J Med Chem (2017) 127: 115-127 [PMID:28038324]
ChEMBL Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells using fluorogenic HDAC substrate 3 after 30 mins by fluorescence assay B 7.89 pIC50 13 nM IC50 Eur J Med Chem (2018) 150: 506-524 [PMID:29549837]
ChEMBL Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate by fluorescence assay B 7.96 pIC50 11 nM IC50 J Med Chem (2016) 59: 8233-8262 [PMID:27541357]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 8.4 pIC50 4 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
ChEMBL Inhibition of N-terminal GST tagged human HDAC6 (1 to 1215 residues) expressed in baculovirus infected insect cells using RHKKAc as substrate in presence of ATP B 8.46 pIC50 3.5 nM IC50 J Med Chem (2017) 60: 8336-8357 [PMID:28953386]
ChEMBL Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay B 8.46 pIC50 3.5 nM IC50 J Med Chem (2016) 59: 8233-8262 [PMID:27541357]
ChEMBL Inhibition of human HDAC6 using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate B 8.46 pIC50 3.5 nM IC50 Bioorg Med Chem Lett (2018) 28: 2636-2640 [PMID:29945795]
ChEMBL Inhibition of HDAC6 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay B 8.7 pIC50 2 nM IC50 J. Med. Chem. (2013) 56: 1772-1776 [PMID:23368884]
histone deacetylase 7/Histone deacetylase 7 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2716] [GtoPdb: 2661] [UniProtKB: Q8WUI4]
ChEMBL Inhibition of HDAC7 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate after 30 mins by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 141: 596-602 [PMID:29102179]
ChEMBL Inhibition of human recombinant HDAC7 protein using Acetyl-Lys (trifluoroacetyl)-AMC as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 6297-6313 [PMID:23627282]
ChEMBL Inhibition of human recombinant HDAC7 using acetyl-Lys(trifluoroacetyl)-AMC as substrate B 4.52 pIC50 >30000 nM IC50 J. Med. Chem. (2013) 56: 7201-7211 [PMID:23964961]
ChEMBL Inhibition of N-terminal GST-tagged human HDAC7 (518 to end residues) using fluorogenic acetyl-Lys(trifluoroacetyl)-AMC substrate incubated for 2 hrs by fluorescence assay B 4.52 pIC50 >30000 nM IC50 Bioorg. Med. Chem. Lett. (2014) 24: 5450-5454 [PMID:25454270]
ChEMBL Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at room temperature in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 4.52 pIC50 >30000 nM IC50 US-8748451-B2. HDAC inhibitors and therapeutic methods of using same (2014)
ChEMBL Inhibition of HDAC7 (unknown origin) B 4.52 pIC50 >30000 nM IC50 Eur J Med Chem (2017) 135: 174-195 [PMID:28453994]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 5.01 pIC50 9700 nM IC50 US-9249087-B2. HDAC inhibitors and therapeutic methods using the same (2016)
ChEMBL Inhibition of HDAC7 (unknown origin) assessed as fluorescence intensity measured after 60 mins incubation at room temperature by trypsin-free microfluidic lab-on-a-chip assay B 6.42 pIC50 379 nM IC50 J. Med. Chem. (2013) 56: 1772-1776 [PMID:23368884]
Histone deacetylase 8 in Schistosoma mansoni (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3797017] [UniProtKB: A5H660]
ChEMBL Inhibition of Schistosoma mansoni KDAC8 using (FAM)-labeled peptide as substrate after 60 mins by microfluidic assay B 5.83 pIC50 1479.11 nM IC50 Bioorg Med Chem (2017) 25: 2105-2132 [PMID:28259528]
histone deacetylase 8/Histone deacetylase 8 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3192] [GtoPdb: 2619] [UniProtKB: Q9BY41]
ChEMBL Inhibition of human HDAC8 B 7.02 pKi 96.2 nM Ki Bioorg. Med. Chem. (2015) 23: 5151-5155 [PMID:25637120]
ChEMBL Inhibition of recombinant human KDAC8 using diacetylated p53 (379 to 382 residues) as substrate by fluorescence assay B 5.63 pIC50 2340 nM IC50 J. Med. Chem. (2016) 59: 1613-1633 [PMID:26681404]
ChEMBL HDAC Activity Assay: HDAC assay is performed using fluorescently-labeled acetylated substrate, which comprises an acetylated lysine side chain. After incubation with HDAC, deacetylation of the substrate sensitizes the substrate such that, in a second step, treatment with the detection enzyme produces a fluorophore. HDACs 1 and 6 were expressed as full length fusion proteins. Purified proteins were incubated with 50 μM fluorescently-labeled acetylated peptide substrate and test compound for 2 hours at RT in HDAC assay buffer containing 50 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1% DMSO, and 1% BSA. Reactions were terminated by the addition of the Developer after 2 hours, and the development of fluorescence signal, which was relative to the amount of deacetylated peptide, was monitored by time-course measurement of EnVision (PerkinElmer). The HDAC activity was estimated from the slope of time-course measurement of the fluorescence intensity. B 5.9 pIC50